ICM
AUPH icon

IMS Capital Management’s Aurinia Pharmaceuticals AUPH Stock Holding History

IMS Capital Management’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-100
Closed -$1K – 136
2018
Q3 		$1K Buy
+100
New +$561 ﹤0.01% 380

Other funds holding AUPH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

IMS Capital Management's AUPH Position: Q4 2018 in Review

IMS Capital Management sold out of Aurinia Pharmaceuticals (AUPH) in Q4 2018, closing a stake of 100 shares — an estimated $1K sold.

IMS Capital Management first reported a position in AUPH in Q3 2018 and held it in 1 quarter. The position peaked at $1K in Q3 2018. 61 funds tracked by Wall St. Rank hold AUPH as of Q4 2018.

  • IMS Capital Management reported no remaining Aurinia Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • IMS Capital Management sold 100 Aurinia Pharmaceuticals shares in Q4 2018, an estimated $1K.
  • IMS Capital Management first reported a position in Aurinia Pharmaceuticals in Q3 2018 and held it in 1 quarter.
  • IMS Capital Management's Aurinia Pharmaceuticals position peaked at $1K in Q3 2018.
  • 61 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q4 2018.

Based on IMS Capital Management's 13F filing for Q4 2018, filed 7 Feb 2019.